Research progress of immunotherapy for advanced head and neck cancer.

Anchi Sun, Zhiwei Xing, Rongrong Lv, Pengyuan Niu, Bao Zhao, Shiyin Ma, Hui Li

Abstract readReview

In one paragraph

Review in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Anchi SunDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China.

Zhiwei XingDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China.

Rongrong LvDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China.

Pengyuan NiuDepartment of Neurosurgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China.

Bao ZhaoDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China.

Shiyin MaDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China. 3260230068@qq.com.

Hui LiDepartment of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China. lihui@bbmc.edu.cn.

Funding

National Natural Science Foundation of China 81903142National Natural Science Foundation of China (General Program) 82372786

6 · The paper itself

Abstract

Head and neck cancer accounts for about one-fifth of all malignant tumors, and the incidence is increasing year by year. The overall mortality rate was high and the 5-year survival rate was low. At present, the combination of surgery, radiotherapy, and chemotherapy is the main treatment in clinical practice, but the treatment of recurrent or metastatic advanced head and neck cancer is still a challenge. With the rise of immunotherapy, more and more studies on immune checkpoint inhibitors have been conducted. This review summarizes the mechanism, clinical application and safety of immunotherapy for advanced head and neck cancer.

Indexed as

Head and Neck NeoplasmsImmune Checkpoint InhibitorsImmunotherapyHumansImmune Checkpoint InhibitorsAdvanced tumorsCombination therapyHead and neck cancerImmune evasionImmunotherapy

Identifiers

PMID38703250

DOI10.1007/s00405-022-07800-1

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.